BIT Capital GmbH Acquires 5,569 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

BIT Capital GmbH raised its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 8.1% during the fourth quarter, HoldingsChannel reports. The firm owned 73,990 shares of the biotechnology company’s stock after acquiring an additional 5,569 shares during the quarter. Ascendis Pharma A/S accounts for 0.8% of BIT Capital GmbH’s holdings, making the stock its 21st largest position. BIT Capital GmbH’s holdings in Ascendis Pharma A/S were worth $10,186,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Legato Capital Management LLC increased its position in Ascendis Pharma A/S by 7.5% during the 4th quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company’s stock worth $264,000 after purchasing an additional 134 shares in the last quarter. Jones Financial Companies Lllp grew its stake in shares of Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after buying an additional 197 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Ascendis Pharma A/S during the third quarter worth $30,000. GAMMA Investing LLC lifted its stake in shares of Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 214 shares during the last quarter. Finally, Blue Trust Inc. boosted its holdings in shares of Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 328 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Evercore ISI upped their target price on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a report on Tuesday, February 18th. Cantor Fitzgerald upped their price objective on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, February 25th. The Goldman Sachs Group lifted their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. upped their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, March 18th. Finally, Morgan Stanley set a $180.00 price target on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $204.64.

Ascendis Pharma A/S Stock Down 1.7 %

ASND stock opened at $158.28 on Thursday. The firm has a market cap of $9.61 billion, a price-to-earnings ratio of -22.29 and a beta of 0.62. The company’s fifty day simple moving average is $143.11 and its 200 day simple moving average is $136.60. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. Research analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.